Transcatheter aortic valve implantation (TAVI) has matured into a standard treatment option
for patients with severe symptomatic aortic valve stenosis (AS) across the whole spectrum of …

The “Guidelines on the Management of Valvular Heart Disease” were initially published as
the “Guidelines on Non-pharmacological Treatment of Valvular Heart Disease” in 2002 …

Aortic stenosis is the most common valvular disease requiring valve replacement. Valve
replacement therapies have undergone progressive evolution since the 1960s. Over the last …

Background Treatment of aortic-valve disease in young patients still poses challenges. The
Ross procedure offers several potential advantages that may translate to improved long …

Background The COMMENCE trial was conducted to evaluate the safety and effectiveness
of aortic valve replacement using a bioprosthesis with novel RESILIA tissue (Edwards …

Importance There are limited data on outcomes of transcatheter aortic valve replacement
(TAVR) for bicuspid aortic stenosis in patients at low surgical risk. Objective To compare the …

OBJECTIVES Long-term durability of bioprosthetic valves is predominantly limited by
structural valve deterioration. RESILIA™ tissue has exhibited reduced calcification in pre …

Prosthetic heart valves have been commonly used to address the increasing prevalence of
valvular heart disease. The ideal prosthetic heart valve substitute should closely mimic the …

An increasing number of surgically implanted bioprostheses will require re-intervention for
structural valve deterioration. Valve-in-valve transcatheter aortic valve replacement (ViV …

Objective As bioprosthetic aortic valve replacement (AVR) extends to younger cohorts,
tissue durability is of paramount importance. We report 7-year outcomes from an AVR …